BB

File 351:DERWENT WPI 1963-1997/UD=9718;UA=9715;UM=9710
(c)1997 Derwent Info Ltd
*File 351: **** Newly enhanced single file is now ONLINE!! ****
See HELP NEWS 351 for more information.

Set	Items	Description

?t 011171839/9

011171839/9
DIALOG(R)File 351:DERWENT WPI

011171839
WPI Accession No: 97-149764
XRAM Accession No: C97-047964
Cancer metastasis inhibitor - comprises eicosa-pentanoic acid and docosa-hexaenoic acid
Patent Assignee: SAGAMI CHEM RES CENTRE (SAGA)
Number of Countries: 001 Number of Patents: 001
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
JP 9025231	A	19970128	JP 95177171	A	19950713	A61K-031/20	199714 B

Priority Applications (No Kind Date): JP 95177171 A 19950713
Patent Details:

Patent	Kind	Lan	Pg	Filing Notes	Application	Patent
JP 9025231	A		4			

BQ

Abstract (Basic): JP 9025231 A
Cancer metastasis inhibitor comprises eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and/or their deriv. The inhibitor is formulated into powder, granules, capsules, tablets, syrup or elixirs for oral admin.; or injection for parenteral admin.. The amt. of EPA or DHA is 1-90 wt.%, pref. 10-80 wt.%..

USE/ADVANTAGE - The inhibitor is effective against metastasis of cancer, esp., lung cancer. The daily dosage of EPA or DHA is 0.1-5g, pref. 0.5-2.5 g. The inhibitor has low toxicity and shows its effect significantly even with a small amt..

In an example, the Co26 metastatic strains were prepd. from CDF1 mice (22 g, 5 week old) by intravenous injection of Co26 cell and subcutaneous transplantation of lung metastasis on the backs of mice. After subcutaneous injection of Co26 metastatic strain cells (1 ml) on the back of mice, the following ethyl esters (0.1 ml each) were administered orally for 5 days/week over 4 weeks to A-E gp.; oleic acid to (A gp.), linoleic acid to (b gp.) arachidonic acid to (c gp.) EPA to (D gp.) and DHA to (E gp.). 31 days later, counted by Mann-Whitney U-test. The number of lung metastasis of A gp. was 21 out of 13 mice, that of B gp. was 26.5 out of 12 mice, that of C gp. was 19.0 out of 11 mice, that of D gp. was 1.40 out of 12 mice and that of gp. was 9.0 out of 11 mice. The results showed that E gp. (DHA gp.) and D gp. (EPA gp.) had significant lung metastasis inhibitory effects.